Hemoporfin-mediated photodynamic therapy for the treatment of port-wine stain: A multicenter, retrospective study.

Humans Male Child, Preschool Photochemotherapy / methods Port-Wine Stain / drug therapy Photosensitizing Agents / therapeutic use Retrospective Studies Hematoporphyrins

Efficacy Hemoporfin-PDT Large-scale samples Multicenter study Port-wine stain Safety

Journal

Photodiagnosis and photodynamic therapy

ISSN: 1873-1597

Titre abrégé: Photodiagnosis Photodyn Ther

Pays: Netherlands

ID NLM: 101226123

Informations de publication

Date de publication:
Jun 2023

Historique:

received: 13 12 2022

revised: 15 03 2023

accepted: 28 03 2023

medline: 3 7 2023

pubmed: 1 4 2023

entrez: 31 3 2023

Statut: ppublish

Résumé

Hemoporfin-mediated photodynamic therapy (Hemoporfin-PDT) has been approved for port-wine stain (PWS) in China in 2017. This study evaluated the efficacy and safety of Hemoporfin-PDT for PWS in a real life setting and investigated factors that influence the efficacy. A multicenter retrospective study included patients with PWS who underwent Hemoporfin-PDT in 29 hospitals across China and completed at least two months of follow-up. The efficacy was evaluated based on patien photographs. A total of 1679 patients were included. After the first and second sessions of Hemoporfin-PDT, 63.5 and 75.3% of patients responded, respectively. The response rate of purple-type PWS was significantly lower than that of pink-type PWS (OR: 0.71, 95% CI: 0.54-0.94, P < 0.05), and there was no significant difference between thick- and pink-type (OR: 0.72, 95% CI: 0.42-1.22, P > 0.05). The response rate of PWS on the limbs was significantly lower than that on the mid-face (OR: 0.35, 95% CI: 0.23-0.53, P < 0.0001), while no significant difference was observed between PWS on the peripheral part of the face, neck or other parts of the body and PWS on the mid-face (P > 0.05). The response rate was lower in male patients with an age > 3 years or ≤ 6 years (P < 0.05). Previous treatment history did not affect the efficacy (P > 0.05). Hemoporfin-PDT was well tolerated. Patients with PWS have a good response and good tolerance to Hemoporfin-PDT.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

A multicenter retrospective study included patients with PWS who underwent Hemoporfin-PDT in 29 hospitals across China and completed at least two months of follow-up. The efficacy was evaluated based on patien photographs.

RESULTS RESULTS

A total of 1679 patients were included. After the first and second sessions of Hemoporfin-PDT, 63.5 and 75.3% of patients responded, respectively. The response rate of purple-type PWS was significantly lower than that of pink-type PWS (OR: 0.71, 95% CI: 0.54-0.94, P < 0.05), and there was no significant difference between thick- and pink-type (OR: 0.72, 95% CI: 0.42-1.22, P > 0.05). The response rate of PWS on the limbs was significantly lower than that on the mid-face (OR: 0.35, 95% CI: 0.23-0.53, P < 0.0001), while no significant difference was observed between PWS on the peripheral part of the face, neck or other parts of the body and PWS on the mid-face (P > 0.05). The response rate was lower in male patients with an age > 3 years or ≤ 6 years (P < 0.05). Previous treatment history did not affect the efficacy (P > 0.05). Hemoporfin-PDT was well tolerated.

CONCLUSION CONCLUSIONS

Patients with PWS have a good response and good tolerance to Hemoporfin-PDT.

Identifiants

DOI: 10.1016/j.pdpdt.2023.103545 PMID: 37001715

pubmed: 37001715

pii: S1572-1000(23)00273-9

doi: 10.1016/j.pdpdt.2023.103545

pii:

doi:

Substances chimiques

hematoporphyrin monomethyl ether 0

Photosensitizing Agents 0

Hematoporphyrins 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

103545